Via Nova Therapeutics discovers and develops novel, first-in-class antiviral therapies targeting acute and subacute viral infections. The company utilizes state-of-the-art drug discovery modalities to create treatments that diverge from the industry focus on chronic viral diseases. Their goal is to efficiently advance this pipeline of new antivirals into clinical settings.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antiviral therapies primarily target chronic viral infections, leaving a significant unmet need for effective treatments against acute and subacute viral infections like influenza and adenovirus. Existing options for these infections are often inadequate, highlighting the necessity for novel therapeutic interventions.
Solution
Via Nova Therapeutics is developing first-in-class antiviral therapies specifically designed to combat acute and subacute viral infections. By focusing on this underserved area, the company aims to provide effective treatments for diseases where current options fall short. Via Nova employs state-of-the-art drug discovery methods to identify and develop novel antivirals, with a commitment to advancing these treatments through the clinical pipeline. The company's approach is driven by the belief that advancements in rapid diagnostics for acute and subacute infections create new opportunities for bringing targeted therapies to patients.
Target Audience
The primary target audience includes patients suffering from acute and subacute viral infections, as well as healthcare providers seeking more effective treatment options for these conditions.
Features
- Focus on discovering and developing novel, first-in-class antiviral therapies.
- Targeting acute and subacute viral infections, including influenza and adenovirus.
- Utilization of state-of-the-art drug discovery methods.
- Commitment to advancing a pipeline of antiviral candidates.